

Fernando Pastor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7387581/publications.pdf>

Version: 2024-02-01

43
papers

2,103
citations

304743

22
h-index

330143

37
g-index

43
all docs

43
docs citations

43
times ranked

2718
citing authors

#	ARTICLE	IF	CITATIONS
1	Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 376-386.	8.2	277
2	Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. <i>Nature</i> , 2010, 465, 227-230.	27.8	231
3	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. <i>Seminars in Oncology</i> , 2015, 42, 640-655.	2.2	179
4	An RNA toolbox for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 751-767.	46.4	171
5	Clinical Benefit Associated With Idiomatic Vaccination in Patients With Follicular Lymphoma. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1292-1301.	6.3	155
6	Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers. <i>Molecular Therapy</i> , 2011, 19, 1878-1886.	8.2	115
7	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. <i>Journal of Translational Medicine</i> , 2017, 15, 104.	4.4	100
8	CD28 Aptamers as Powerful Immune Response Modulators. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e98.	5.1	99
9	Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 192-204.	5.1	71
10	Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors. <i>Clinical Cancer Research</i> , 2013, 19, 1054-1062.	7.0	68
11	2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. <i>Biomaterials</i> , 2015, 67, 274-285.	11.4	63
12	MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. <i>Oncotarget</i> , 2016, 7, 23182-23196.	1.8	58
13	Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma. <i>BioMed Research International</i> , 2015, 2015, 1-15.	1.9	53
14	Identification of TIM3 2-Fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 4522-4530.	1.8	44
15	Targeting inhibition of Foxp3 by a CD28 2-Fluoro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. <i>Biomaterials</i> , 2016, 91, 73-80.	11.4	43
16	In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study' TIM3 Aptamers Binding. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e376.	5.1	40
17	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. <i>Molecular Therapy</i> , 2019, 27, 1878-1891.	8.2	38
18	Aptamer-iRNAs as Therapeutics for Cancer Treatment. <i>Pharmaceuticals</i> , 2018, 11, 108.	3.8	37

#	ARTICLE	IF	CITATIONS
19	The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 930-941.	1.2	29
20	Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA). <i>PLoS ONE</i> , 2017, 12, e0185169.	2.5	29
21	Aptamers: A Feasible Technology in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	2.2	26
22	Aptamers: A New Technological Platform in Cancer Immunotherapy. <i>Pharmaceuticals</i> , 2016, 9, 64.	3.8	25
23	Anti-Inflammatory Cytokines Induce Lipopolysaccharide Tolerance in Human Monocytes Without Modifying Toll-Like Receptor 4 Membrane Expression. <i>Scandinavian Journal of Immunology</i> , 2004, 59, 553-558.	2.7	23
24	Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14. <i>Microbes and Infection</i> , 2004, 6, 990-995.	1.9	22
25	Prolonged idiotypic vaccination against follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 47-53.	1.3	21
26	Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. <i>World Journal of Clinical Oncology</i> , 2012, 3, 142.	2.3	17
27	Idiotype Vaccines for Human B-Cell Malignancies. <i>Current Pharmaceutical Design</i> , 2010, 16, 300-307.	1.9	15
28	Idiotype vaccines for lymphoma therapy. <i>Expert Review of Vaccines</i> , 2011, 10, 801-809.	4.4	11
29	Oligonucleotide-Based Therapies for Renal Diseases. <i>Biomedicines</i> , 2021, 9, 303.	3.2	10
30	BiovaXD [®] : a customized idiotype vaccine for the treatment of B-cell lymphoma. <i>Expert Review of Vaccines</i> , 2011, 10, 1661-1669.	4.4	7
31	Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. <i>World Journal of Clinical Oncology</i> , 2011, 2, 237.	2.3	5
32	Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1653-1660.	2.1	5
33	Idiotype Vaccine Production Using Hybridoma Technology. <i>Methods in Molecular Biology</i> , 2014, 1139, 367-387.	0.9	4
34	Successful idiotypic vaccination following stem cell allotransplant in lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 881-884.	1.3	3
35	Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy. <i>Molecular Therapy</i> , 2018, 26, 675-677.	8.2	3
36	Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. <i>Oncolmmunology</i> , 2018, 7, e1450711.	4.6	3

#	ARTICLE	IF	CITATIONS
37	Tumor-targeted costimulation by using bi-specific aptamers. <i>Cancer Cell & Microenvironment</i> , 2016, 3, e1333.	0.8	1
38	Aptamers as a Promising Therapeutic Tool for Cancer Immunotherapy. , 2017, , .		1
39	Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 21427.	3.3	1
40	IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS. <i>Neuro-Oncology</i> , 2021, 23, i28-i28.	1.2	0
41	Biological Efficacy of a Dendritic Cell-Based Vaccine in a Patient with Metastatic Colorectal Cancer. <i>Journal of Cancer Research Updates</i> , 0, , .	0.3	0
42	Idiotypic Vaccination: Still a Unique form of Cancer Immunotherapy for Follicular Lymphoma after 20 Years. <i>Advances in Cancer: Research & Treatment</i> , 2013, , 1-13.	0.0	0
43	Immune-checkpoint blockade aptamers as a feasible clinical alternative to monoclonal antibodies. <i>Cancer Cell & Microenvironment</i> , 0, , .	0.8	0